Study on the effect of different doses of Ermiaosan on inflammatory response in CIA model rats
Abstract
Objective: To investigate the effect of different doses of Ermiaosan on improving the inflammatory response in collagen-induced arthritis (CIA) model rats. Methods: The CIA rat model was established and randomly divided into the model group (CIA group), and low, medium, and high dose Ermiaosan groups. Each group was treated with the corresponding drugs, while the healthy control group and the model group were given an equal volume of saline by gavage. The expression of inflammatory factors IL-1β, IL-6, and TNF-α in each group was detected using ELISA, and the pathological changes in rat joints were observed using Masson staining. Results: Rats in the CIA group showed significant tissue damage, tissue proliferation, and inflammatory infiltration in the joints. The low, medium, and high dose Ermiaosan groups exhibited reduced joint tissue destruction and proliferation. Different doses of Ermiaosan were able to alleviate joint lesions in CIA rats. The expression levels of IL-1β, IL-6, and TNF-α in serum were significantly reduced in all dose groups (P<0.05). Compared with the CIA group, the medium and high dose groups showed consistent therapeutic effects, both significantly better than the low dose group. Conclusion: The medium dose of Ermiaosan achieved satisfactory therapeutic effects on the inflammatory response in CIA model rats. Ermiaosan may exert its therapeutic effects on RA by inhibiting inflammatory factors.
References
[1] Khoja S.S., Patterson C.G., Goodpaster B.H., et al. Skeletal muscle fat in individuals with rheumatoid arthritis compared to healthy
adults[J]. Exp Gerontol, 2020, 129:110768.
[2] Zhang Y.B., Liu Z.M., Xiong L.S. Progress in the pathogenesis and treatment methods of rheumatoid arthritis[J]. Chinese Journal
of Cellular And Molecular Immunology. 2005, 9:88-91.
[3] Yi H.M., Lu Y.W., Xu M.Q., Yu G.R. Effects of the main components of Ermiaosan, berberine hydrochloride, and atractylenolide
III on LPS-induced inflammatory activation of BV2 microglia[J]. Modern Journal of Integrated Traditional Chinese And Western Medicine,
2021, 30:3328-3333,3348.
[4] Li Y.T., Liu J.S., Feng Y.M., Li Z. Clinical application of Ermiaosan in the treatment of difficult diseases with damp-heat syndrome[J]. Journal of Hebei Traditional Chinese Medicine And Pharmacology, 2022, 4:60-64.
[5] Lu Y.Z., Hu Q.H., Wang X., Ouyang Z., Kong L.D. Effects of aqueous extract of Ermiaowan on uric acid imbalance and related
genes and protein levels in hyperuricemic mice. Chinese Traditional And Herbal Drugs, 2012, 3:418-423.
[6] Lu W.J., Li Z., Hao H.Q., et al. Effects of traditional Chinese medicine formula Ermiaosan on Gnαq expression and improvement of
inflammatory response in CIA model rats[J]. Chinese Journal of Immunology, 2024, 06:1222-1227.
[7] Trentham D.E., Townes A.S., Kang A.H. Autoimmunity to type II collagen: an experimental model of arthritis [J]. J Exp, 1977, 3:
857-866.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
